Palavras-chave
Mediadores da inflamação
Transtorno depressivo maior
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Analisar a associação entre níveis de marcadores inflamatórios sistêmicos e a gravidade dos sintomas em pacientes adultos diagnosticados com Transtorno Depressivo Maior. Métodos: Trata-se de uma revisão integrativa da literatura realizada através das bases PubMED, Biblioteca Virtual em Saúde (BVS) e Periódico CAPES, usando os descritores: “Depressive Disorder, Major”, “Inflammation Mediators” e “Depression”, e obtendo o truncamento de pesquisa: (Depressive Disorder, Major) AND (Inflammation Mediators) AND (Depression). Foram encontrados 1.731 artigos, filtrados conforme critérios de inclusão (idiomas português, inglês e espanhol; período de 2021 a 2026; artigos completos) e exclusão (artigos duplicados, resumos, fora do escopo). Resultados: O transtorno depressivo maior está associado a um estado de inflamação sistêmica de baixo grau, com elevação de citocinas pró-inflamatórias e desequilíbrios imunológicos. Esses processos influenciam diretamente vias neurobiológicas, como o metabolismo do triptofano e a neurotransmissão serotoninérgica, contribuindo para a gravidade dos sintomas. Além disso, a inflamação se relaciona a alterações estruturais e funcionais cerebrais e ao aumento do risco cardiometabólico, reforçando seu papel central na fisiopatologia do TDM. Conclusão: A inflamação sistêmica desempenha papel central na fisiopatologia e na gravidade do transtorno depressivo maior. Sua compreensão amplia possibilidades de estratificação de risco e de abordagens terapêuticas mais direcionadas.
Referências
AKTER M, et al. Evaluation of serum MIP-1β and MCP-2 levels in major depressive disorder: A case-control study. PloS One, 2024; 19(6): e0305734.
AL-KACHAK A, et al. Histone serotonylation in dorsal raphe nucleus contributes to stress- and antidepressant-mediated gene expression and behavior. Nature Communications, 2024; 15(1): 5042.
ARTEAGA-HENRIQUEZ G, et al. Activation and deactivation steps in the tryptophan breakdown pathway in major depressive disorder: A link to the monocyte inflammatory state of patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2021; 107(110226): 110226.
BARDE S, et al. Substance P, NPY, CCK and their receptors in five brain regions in major depressive disorder with transcriptomic analysis of locus coeruleus neurons. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 2024; 78(1): 54–63.
BARTLETT EA, et al. Serotonin transporter binding in major depressive disorder: impact of serotonin system anatomy. Molecular Psychiatry, 2022; 27(8): 3417–3424.
BORSINI A, et al. Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis. Molecular Psychiatry, 2021; 26(11): 6773–6788.
CAI Y, et al. Association between increased serum interleukin-8 levels and improved cognition in major depressive patients with SSRIs. BMC Psychiatry, 2023; 23(1): 122.
CHEN X, et al. Stress induces behavioral disorders by promoting microglial phagocytosis via decreasing neuronal Dkk3. Molecular Psychiatry, 2025; 30(12): 5731–5748.
DAWOOD S, et al. Inflammation and serotonin deficiency in major depressive disorder: molecular docking of antidepressant and anti-inflammatory drugs to tryptophan and indoleamine 2,3-dioxygenases. Bioscience Reports, 2022; 42(5).
DO SACRAMENTO PM, et al. Major depression favors the expansion of Th17-like cells and decrease the proportion of CD39+Treg cell subsets in response to myelin antigen in multiple sclerosis patients. Cellular and Molecular Life Sciences, 2022; 79(6): 298.
FANG Y, et al. Fluoxetine inhibited the activation of A1 reactive astrocyte in a mouse model of major depressive disorder through astrocytic 5-HT2BR/β-arrestin2 pathway. Journal of Neuroinflammation, 2022; 19(1): 23.
GARÉS-CABALLER M, et al. Immune-inflammatory biomarkers predict cognition and social functioning in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: A 1-year follow-up study. Frontiers in Neurology, 2022; 13(1): 883927.
GONZÁLEZ-ARIAS C, et al. Dysfunctional serotonergic neuron-astrocyte signaling in depressive-like states. Molecular Psychiatry, 2023; 28(9): 3856–3873.
HIDESE S, et al. Plasma neuropeptide levels in patients with schizophrenia, bipolar disorder, or major depressive disorder and healthy controls: A multiplex immunoassay study. Neuropsychopharmacology Reports, 2023; 43(1): 57–68.
HUANG J, et al. Mesenchymal stromal cells alleviate depressive and anxiety-like behaviors via a lung vagal-to-brain axis in male mice. Nature Communications, 2023; 14(1): 7406.
ISLAM S, et al. Altered serum adiponectin and interleukin-8 levels are associated in the pathophysiology of major depressive disorder: A case-control study. PloS One, 2022; 17(11): e0276619.
KLAUS F, et al. Common and disorder-specific upregulation of the inflammatory markers TRAIL and CCL20 in depression and schizophrenia. Scientific Reports, 2021; 11(1): 19204.
KOLOI A, et al. Immunometabolic pathways: Investigating mediators of major depressive disorder and atherosclerotic cardiovascular disease comorbidity. Biological Psychiatry Global Open Science, 2025; 5(5): 100528.
LAMON-FAVA S, et al. Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 2023; 48(6): 929–935.
LANGHEIN M, et al. Association between peripheral inflammation and free-water imaging in Major Depressive Disorder before and after ketamine treatment - A pilot study. Journal of Affective Disorders, 2022; 314(1): 78–85.
LENGVENYTE A, et al. Integrating cellular and soluble immune signatures of major depression with and without recent suicide attempts. Translational Psychiatry, 2025; 15(1): 377.
LI G, et al. Association between major depressive disorder or depressive symptoms and the risk of vascular complications among patients with type 2 diabetes, and the mediating role of metabolic biomarkers: an analysis of the UK Biobank cohort. EClinicalMedicine, 2025; 79(102982): 102982.
QIU T, et al. Prospective study on Maresin-1 and cytokine levels in medication-naïve adolescents with first-episode major depressive disorder. Frontiers in Psychiatry, 2023; 14(1): 1132791.
RIGA MS, et al. Scn1a haploinsufficiency in the prefrontal cortex leads to cognitive impairment and depressive phenotype. Brain: A Journal of Neurology, 2024; 147(12): 4169–4184.
SAVITZ J, et al. Nuclear factor kappa-B cell (NF-κB), interferon regulatory Factor, and glucocorticoid receptor pathway activation in major depressive Disorder: The role of cytomegalovirus infection. Brain, Behavior, and Immunity, 2025; 123(1): 1052–1060.
YU H, et al. Lipopolysaccharide preconditioning restricts microglial overactivation and alleviates inflammation-induced depressive-like behavior in mice. Brain Sciences, 2023; 13(4): 549.